Life's essential 8 and mortality in US adults with metabolic dysfunction-associated steatotic liver disease

被引:0
|
作者
Zhang, Yingying [1 ]
Wang, Pingping [2 ]
Tu, Fan [1 ]
Kang, Hao [3 ]
Fu, Chengfeng [4 ]
机构
[1] Jiangnan Univ, Affiliated Wuxi Hosp 5, Med Lab Ctr, 1215 Guangrui Rd, Wuxi 214005, Jiangsu, Peoples R China
[2] Yangzhou Univ, Taizhou Peoples Hosp 2, Dept Clin Lab, Taizhou, Jiangsu, Peoples R China
[3] Jiangnan Univ, Affiliated Wuxi Hosp 5, Res Ctr Clin Med Sci, Wuxi, Jiangsu, Peoples R China
[4] Second Peoples Hosp Banan Dist, Resp & Crit Care Med, 18 Huaxi New Village,Huaxi St, Chongqing 400054, Peoples R China
关键词
MASLD; Life's essential 8; All-cause mortality; CVD mortality; National health and nutrition examination survey; AMERICAN HEART ASSOCIATIONS; CARDIOVASCULAR HEALTH; METAANALYSIS; OUTCOMES; METRICS; NHANES; RISK;
D O I
10.1186/s12889-024-20919-6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to increased all-cause mortality due to metabolic dysfunctions like obesity, diabetes, and cardiovascular diseases. This study examines the association between Life's Essential 8 (LE8) scores and both all-cause and cardiovascular disease (CVD) mortality in MASLD participants. Methods Data from 5,916 MASLD participants in the NHANES (2005-2018) were analyzed. Associations between LE8 scores and all-cause and CVD mortality were assessed using Cox proportional hazards models, with follow-up until December 31, 2019. Dose-response relationships and survival differences were evaluated using Kaplan-Meier survival curves and Restricted Cubic Spline models. Results Over a median follow-up of 7.6 years, moderate and high LE8 scores were associated with 33% (HR: 0.67; 95% CI: 0.56-0.79) and 47% (HR: 0.53; 95% CI: 0.33-0.84) lower risk of all-cause mortality, respectively, compared to low scores. For CVD mortality, the adjusted HRs were 0.56 (95% CI: 0.41-0.78) and 0.35 (95% CI: 0.12-1.0). Higher LE8 scores were significantly associated with reduced cumulative incidence of all-cause and CVD mortality (log-rank P < 0.001). A 10-point increase in health behavior scores, particularly in diet, physical activity, and nicotine exposure, was linked to an 11% reduction in all-cause mortality risk and an 11% reduction in CVD mortality risk. Among health factors, only blood glucose showed a significant association with CVD mortality. Conclusion Higher LE8 scores in MASLD patients are associated with lower mortality risk, suggesting the potential value of promoting cardiovascular health in this population. Further research is needed to confirm these associations.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Advances in research on metabolic dysfunction-associated steatotic liver disease
    Wang, Jiawang
    Wang, Zhongyu
    Yu, Yao
    Cheng, Si
    Wu, Jianping
    LIFE SCIENCES, 2025, 362
  • [32] Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
    Li, Yamei
    Qi, Ping
    Song, Si -Yuan
    Wang, Yiping
    Wang, Hailian
    Cao, Peng
    Liu, Yu 'e
    Wang, Yi
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [33] Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease
    Chen, Mei-jing
    Chen, Ying
    Lin, Jin-qing
    Hu, Rong
    Liu, Dun
    Chen, Jing-yi
    Li, Ka
    Jiang, Xiao-ying
    FRONTIERS IN NUTRITION, 2025, 11
  • [34] Natural history of metabolic dysfunction-associated steatotic liver disease
    Lekakis, Vasileios
    Papatheodoridis, George, V
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 3 - 10
  • [35] Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
    Ni, Keying
    Meng, Lina
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [36] Vitamin E in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Kountouras, Jannis
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 40 (02) : 551 - 552
  • [37] Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
    El Hussein, Mohamed
    Favell, Daniel
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2025, 21 (02):
  • [38] Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease
    Cherubini, Alessandro
    Della Torre, Sara
    Pelusi, Serena
    Valenti, Luca
    TRENDS IN MOLECULAR MEDICINE, 2024, 30 (12) : 1126 - 1136
  • [39] Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Scarpellini, Emidio
    Scarcella, Marialaura
    Tack, Jan F.
    Scarlata, Giuseppe Guido Maria
    Zanetti, Michela
    Abenavoli, Ludovico
    ANTIOXIDANTS, 2024, 13 (11)
  • [40] Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rodriguez, Luis A.
    Schmittdiel, Julie A.
    Liu, Liyan
    Macdonald, Brock A.
    Balasubramanian, Sreepriya
    Chai, Krisna P.
    Seo, Suk I.
    Mukhtar, Nizar
    Levin, Theodore R.
    Saxena, Varun
    JAMA NETWORK OPEN, 2024, 7 (07) : e2421019